Figure 8.
MAP7D3 is associated with angiogenesis drugs. (A–E) Molecular docking of MAP7D3 with the angiogenesis-targeting drugs sunitinib, Vandetanib, Thalidomide, Lenalidomide, and Cabozantinib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.